Vitrolife AB (publ) (STO:VITR)

Vitrolife AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 25, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	20,056	29,110	26,361	25,210	75,821	23,425
Market Cap Growth	-19.66%	10.43%	4.57%	-66.75%	223.67%	9.27%
Enterprise Value	21,129	30,238	27,740	26,973	71,131	22,662
Last Close Price	148.10	213.43	192.05	182.98	548.57	210.86
PE Ratio	44.20	56.74	-	63.99	222.35	81.67
Forward PE	34.09	39.23	35.66	36.02	113.91	63.93
PS Ratio	5.66	8.07	7.51	7.80	45.11	18.81
PB Ratio	1.51	2.13	2.07	1.51	4.94	11.61
P/TBV Ratio	-	-	-	-	-	17.43
P/FCF Ratio	37.21	35.72	38.21	43.10	211.20	66.99
P/OCF Ratio	28.94	32.10	34.82	39.64	197.45	65.72
PEG Ratio	2.86	1.22	1.22	1.22	1.22	1.22
EV/Sales Ratio	5.97	8.38	7.90	8.34	42.31	18.19
EV/EBITDA Ratio	18.83	25.91	25.06	27.22	140.57	53.84
EV/EBIT Ratio	30.40	38.23	37.59	41.69	165.81	61.73
EV/FCF Ratio	39.20	37.10	40.20	46.11	198.14	64.81
Debt / Equity Ratio	0.15	0.15	0.16	0.13	0.16	0.03
Debt / EBITDA Ratio	1.78	1.72	1.83	2.18	4.74	0.14
Debt / FCF Ratio	3.70	2.56	3.03	3.80	6.91	0.18
Asset Turnover	0.21	0.21	0.19	0.16	0.16	0.56
Inventory Turnover	3.63	3.52	3.75	4.05	2.46	2.32
Quick Ratio	2.62	2.65	2.59	1.80	1.11	6.78
Current Ratio	3.41	3.34	3.44	2.53	1.48	7.99
Return on Equity (ROE)	3.45%	3.90%	-26.14%	2.46%	3.96%	15.09%
Return on Assets (ROA)	2.58%	2.93%	2.50%	2.02%	2.47%	10.33%
Return on Capital (ROIC)	2.85%	3.24%	2.73%	2.20%	2.69%	11.61%
Return on Capital Employed (ROCE)	4.30%	4.70%	4.70%	3.20%	2.30%	17.30%
Earnings Yield	2.27%	1.76%	-14.61%	1.56%	0.45%	1.23%
FCF Yield	2.69%	2.80%	2.62%	2.32%	0.47%	1.49%
Dividend Yield	0.74%	0.52%	0.52%	0.46%	0.15%	0.38%
Payout Ratio	32.83%	26.32%	-	27.66%	25.51%	-
Buyback Yield / Dilution	-0.10%	-0.09%	-	-18.12%	-5.60%	-
Total Shareholder Return	0.64%	0.42%	0.52%	-17.66%	-5.45%	0.38%

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.